Management of Prolonged Activated Partial Thromboplastin Time (aPTT)

Introduction to Prolonged aPTT

An isolated prolonged aPTT can result from therapeutic anticoagulation, such as unfractionated heparin therapy, as recommended by the European Society of Cardiology and American College of Critical Care 1

The European Society of Cardiology and American College of Critical Care recommend reviewing medication history to identify anticoagulant use, repeating the aPTT test to rule out pre-analytical errors, and performing a mixing study to determine the underlying cause of prolonged aPTT 1, 2
The mixing study can help differentiate between factor deficiency and the presence of an inhibitor, with correction of aPTT with normal plasma suggesting factor deficiency 1, 2

The target aPTT range for therapeutic anticoagulation is 1.5-2.3 times the control value, typically 46-70 seconds, as recommended by the European Society of Cardiology and American College of Critical Care 1
The monitoring frequency for aPTT is every 6 hours after starting therapy or after any dosage change, with dose adjustment following a weight-based nomogram 1
The dose adjustment nomogram recommends:
aPTT (s) Bolus (U/kg) Infusion Adjustment (U/kg/h)
<35 80 Increase by 4
35-45 40 Increase by 2
46-70 No change No change
71-90 - Reduce by 2
>90 - Stop for 1h, then reduce by 3
1

For patients with lupus anticoagulant, usually no treatment is needed for the prolonged aPTT itself, but anticoagulation therapy may be required if thrombosis is present, as recommended by the American College of Cardiology 1
For patients with acquired factor inhibitors, immunosuppression with corticosteroids may be necessary, with consideration of rituximab or cyclophosphamide for refractory cases 1
The American College of Cardiology recommends targeting an aPTT range of 1.5-2.5 times control value (typically 45-75 seconds) for heparin therapy 3
Monitoring of aPTT should be performed 6 hours after any dosage change of heparin, as recommended by the American Heart Association 3

Anti-Xa monitoring should be considered if baseline PTT is abnormal, with a target range of 0.3-0.7 IU/mL, as recommended by the American College of Chest Physicians 3, 4, 5
Protamine sulfate (1 mg for every 100 units of heparin given in previous 2-3 hours, maximum 50 mg) should be used for reversal of heparin if needed, as recommended by the American Heart Association 3, 6
If the PTT is supratherapeutic (>75 seconds), reduce heparin dose according to institutional nomogram 7
For a patient with a PTT > 100 seconds, administer protamine sulfate at a dose of 1 mg for every 100 units of heparin given in the previous 2-3 hours (maximum single dose 50 mg) to reverse heparin-induced anticoagulation, as recommended by the American College of Critical Care 6

For severe bleeding with elevated PTT, identify and treat the underlying cause, and consider fresh frozen plasma (15 ml/kg) for established coagulopathy, with a target fibrinogen level >1 g/L, as recommended by the American Society of Anesthesiologists 8
Platelet transfusion should be considered if count <75 × 10⁹/L in patients with severe bleeding and elevated PTT, as recommended by the American Society of Anesthesiologists 8
Anticoagulation therapy (typically warfarin) is recommended for patients with thrombosis, and for patients requiring heparin, use anti-Xa monitoring rather than PTT, as stated by the National Comprehensive Cancer Network 9

In inflammatory states, such as COVID-19, anti-Xa monitoring may be more reliable than aPTT for UFH monitoring, as suggested by the American Society of Anesthesiologists 10
For patients requiring heparin therapy who have baseline aPTT prolongation, anti-Xa monitoring is preferred, according to the American College of Chest Physicians and the American College of Critical Care 11, 5
Lupus Anticoagulant is the most common inhibitor causing prolonged aPTT, and is paradoxically associated with thrombosis rather than bleeding, with a presence of up to 45% in COVID-19 patients, as reported by the International Society on Thrombosis and Haemostasis 11